{
    "nctId": "NCT03253796",
    "officialTitle": "A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis",
    "inclusionCriteria": "* Is not of reproductive potential, or is of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner while receiving trial medication or within 6 months after the last dose of trial medication\n* Has chronic back pain of \u22653 months duration by history\n* Has physician-diagnosed active non-radiographic axial spondyloarthritis (nr-axSpA) with disease duration \\<= 5 years\n* Meets one of the following criteria:\n\n  1. Has active inflammation on magnetic resonance imaging (MRI) highly suggestive of sacroiliitis associated with spondyloarthropathy and 1 or more of the following spondyloarthritis (SpA) characteristics:\n\n     * Inflammatory back pain\n     * Arthritis (physician-diagnosed)\n     * Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia)\n     * Dactylitis (physician-diagnosed)\n     * Psoriasis (physician-diagnosed)\n     * History of physician-diagnosed inflammatory bowel disease (IBD)\n     * History of uveitis confirmed by an ophthalmologist\n     * Good response to nonsteroidal anti-inflammatory drugs (NSAID)\n     * Family history of SpA (presence of ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD)\n     * Elevated C-reactive protein (CRP)\n\n       * Human leukocyte antigen B27 (HLA-B27)+ gene OR\n  2. Has a HLA-B27+ gene and 2 or more of the following SpA characteristics:\n\n     * Inflammatory back pain\n     * Arthritis (physician-diagnosed)\n     * Enthesitis (heel) physician-diagnosed (spontaneous pain or tenderness at examination of the site of the insertion of the Achilles tendon or plantar fascia)\n     * Dactylitis (physician-diagnosed)\n     * Psoriasis (physician-diagnosed)\n     * History of physician-diagnosed inflammatory bowel disease (IBD)\n     * History of uveitis confirmed by an ophthalmologist\n     * Good response to nonsteroidal anti-inflammatory drugs (NSAID)\n     * Family history of SpA (presence of ankylosing spondylitis, psoriasis, acute uveitis, reactive arthritis, or IBD)\n     * Elevated C-reactive protein (CRP)\n* Has elevated CRP at Screening or evidence of active inflammation in the sacroiliac joints on MRI\n* Has an Ankylosing Spondylitis Disease Activity Score (ASDAS) \\>= 2.1 at Screening\n* Shows high disease activity at Screening and Baseline of both a Total Back Pain score of \u22654 and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of \\>= 4\n* Has an acceptable history of NSAID use\n* Has no history of untreated latent or active tuberculosis (TB) prior to Screening\n* Has had no recent close contact with a person with active TB or, if there has been such contact, will undergo additional evaluations and receive appropriate treatment for latent TB\n* Agrees to undergo screening for hepatitis B virus (HBV) and demonstrates negative results for hepatitis B surface antigen (HBsAg) and HBV deoxyribonucleic acid (DNA)\n* Must have minimum age of 18 Years\n* Must have maximum age of 45 Years",
    "exclusionCriteria": "* Has bilateral sacroiliitis Grade 2 or unilateral sacroiliitis Grade 3 or Grade 4 on conventional x-rays\n* Is a nursing or pregnant female, or intends to become pregnant within 6 months after receiving trial medication\n* Intends to donate eggs (female participants) or sperm (male participants) while receiving trial medication or within 6 months after trial medication\n* Has any clinically significant condition or situation that would interfere with the trial evaluations or participation in the trial\n* Has ever received any cytotoxic drugs, including chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents\n* Has received any treatment listed below more recently than the indicated off-drug period prior to Screening\n\n  * \u2022 Disease-modifying anti-rheumatic drugs (30 days off drug)\n  * \u2022 Live vaccinations (3 months off drug)\n  * \u2022 Investigational medications (30 days or 5 half-lives off drug, whichever is longer)\n  * \u2022 Bacille Calmette-Guerin (BCG) vaccination (12 months off drug)\n* Has any systemic inflammatory condition, including psoriatic arthritis, active Lyme disease, systemic lupus erythematosus, infectious arthritis, vasculitis, parvovirus infection, rheumatoid arthritis, active uveitis, or active IBD\n* Has a history of latent or active granulomatous infection prior to Screening\n* Had a nontuberculous mycobacterial infection or opportunistic infection within 6 months prior to Screening\n* Has a history of an infected joint prosthesis, or has received antibiotics for a suspected infection of a joint prosthesis, if that prosthesis has not been removed or replaced\n* Had a serious infection, has been hospitalized for an infection, or has been treated with IV antibiotics for an infection within 2 months prior to Baseline\n* Had a history of, or ongoing, chronic or recurrent infectious disease\n* Is known to be infected with human immunodeficiency virus (HIV) or seropositive for hepatitis C virus (HCV)\n* Has had a chest x-ray within 2 months prior to Screening that shows an abnormality suggestive of a current active infection or malignancy\n* Has a history of lymphoproliferative disease\n* Has had a malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of cervix that has been surgically cured)\n* Has a history of known demyelinating diseases such as multiple sclerosis or optic neuritis\n* Has a history of or concurrent congestive heart failure of any grade\n* Has a transplanted organ (with the exception of a corneal transplant performed \\>= 3 months prior to baseline)\n* Has current signs or symptoms of significant medical illness which could interfere with the trial, or require treatment that might interfere with the trial\n* Is a user of recreational or illicit drugs or has or had a substance abuse (drug or alcohol) problem within the previous 2 years"
}